Salud financiera de hoja de balance de ViroGates

Salud financiera controles de criterios 3/6

ViroGates tiene un patrimonio de los accionistas total de DKK7.1M y una deuda total de DKK5.3M, lo que sitúa su ratio deuda-patrimonio en 74.8%. Sus activos y pasivos totales son DKK14.1M y DKK7.0M respectivamente.

Información clave

74.8%

Ratio deuda-patrimonio

DKK 5.30m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	DKK 7.43m
Patrimonio	DKK 7.09m
Total pasivo	DKK 6.97m
Activos totales	DKK 14.06m

Actualizaciones recientes sobre salud financiera

Recent updates

ViroGates (CPH:VIRO) Is In A Good Position To Deliver On Growth Plans

Mar 06

We're Hopeful That ViroGates (CPH:VIRO) Will Use Its Cash Wisely

Nov 21

Will ViroGates (CPH:VIRO) Spend Its Cash Wisely?

Jun 14

We're Not Very Worried About ViroGates' (CPH:VIRO) Cash Burn Rate

Sep 19

We Think ViroGates (CPH:VIRO) Can Afford To Drive Business Growth

Apr 14

We Think ViroGates (CPH:VIRO) Can Afford To Drive Business Growth

Dec 30

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (DKK13.9M) de VIRO superan a sus pasivos a corto plazo (DKK1.7M).

Pasivo a largo plazo: Los activos a corto plazo de VIRO (DKK13.9M) superan a sus pasivos a largo plazo (DKK5.3M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: VIRO tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de VIRO ha crecido de 0% a 74.8% en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: VIRO tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: VIRO tiene menos de un año de cash runway si el flujo de caja libre sigue creciendo a tasas históricas de 7% cada año.

Salud financiera de hoja de balance de ViroGates

Salud financiera controles de criterios 3/6

Información clave

Actualizaciones recientes sobre salud financiera

ViroGates (CPH:VIRO) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That ViroGates (CPH:VIRO) Will Use Its Cash Wisely

Will ViroGates (CPH:VIRO) Spend Its Cash Wisely?

We're Not Very Worried About ViroGates' (CPH:VIRO) Cash Burn Rate

We Think ViroGates (CPH:VIRO) Can Afford To Drive Business Growth

We Think ViroGates (CPH:VIRO) Can Afford To Drive Business Growth

Recent updates

Third quarter 2024 earnings released

New major risk - Revenue size

ViroGates A/S Maintains Earnings Guidance for the Full-Year of 2024

Second quarter 2024 earnings released

First quarter 2024 earnings released

Full year 2023 earnings released

ViroGates A/S to Report Fiscal Year 2023 Results on Mar 21, 2024

New major risk - Shareholder dilution

ViroGates A/S has filed a Follow-on Equity Offering in the amount of DKK 15.077282 million.

Third quarter 2023 earnings released

ViroGates A/S Announces Positive Results from a Randomized Controlled Clinical Trial on Supar-Guided Antibody Treatment in Sepsis

Virogates Provides Earnings Guidance for 2023

Second quarter 2023 earnings released

New major risk - Market cap size

First quarter 2023 earnings released

Full year 2022 earnings released

ViroGates (CPH:VIRO) Is In A Good Position To Deliver On Growth Plans

ViroGates A/S Announces CE-IVD approval for suPARnostic® TurbiLatex on the Roche Diagnostics cobas® Pure and Pro instrument platforms

ViroGates A/S Announces Chief Financial Officer Changes

ViroGates A/S to Report Fiscal Year 2022 Results on Mar 23, 2023

ViroGates A/S Announces Executive Changes

We're Hopeful That ViroGates (CPH:VIRO) Will Use Its Cash Wisely

ViroGates A/S Announces the Publication of A New Study That Shows SsuPAR upar Causes Cardiovascular Disease

ViroGates announces CE-IVD approval for suPARnostic® TurbiLatex on the Beckman Coulter AU5800 platform

Second quarter 2022 earnings released

ViroGates A/S Provides Revenue Guidance for the Year 2022 and 2023

Will ViroGates (CPH:VIRO) Spend Its Cash Wisely?

High number of new directors

ViroGates A/S Announces Board Changes

ViroGates Announces the CE-Ivd Accreditation of Its Finger-Prick Blood-Testing Product, Suparnostic® Poc+

First quarter 2022 earnings released

ViroGates A/S announces successful finalization of the development project with DIESSE Diagnostica Senese S.p.A

Third quarter 2021 earnings released

We're Not Very Worried About ViroGates' (CPH:VIRO) Cash Burn Rate

Second quarter 2021 earnings released

ViroGates A/S and the Hellenic Institute for the Study of Sepsis Announce Positive Top-Line Results from the Save-More Study

First quarter 2021 earnings released: kr.1.37 loss per share (vs kr.2.04 loss in 1Q 2020)

We Think ViroGates (CPH:VIRO) Can Afford To Drive Business Growth

ViroGates A/S Announces Clinical Routine Use in Greece

New 90-day high: kr.94.00

ViroGates A/S Announces a New Private Hospital as Clinical Routine Customer in Spain

ViroGates A/S Announces Initiation of A Clinical Trial with Hiss to Clinically Validate Its Commercial Biomarker Test for Guiding Early Anakinra Treatment of Covid-19 Patients Across 42 Hospitals

ViroGates A/S Announces Delay in the Development and Launch of suPARnostic POC+ Product

We Think ViroGates (CPH:VIRO) Can Afford To Drive Business Growth

ViroGates A/S to Report Q3, 2021 Results on Nov 11, 2021

ViroGates A/S to Report Q2, 2021 Results on Aug 19, 2021

ViroGates Announces Receipt of the First Order from Mikkeli Central Hospital in Finland

New 90-day high: kr.67.50

Third quarter earnings released

Virogates Announces Receipt of A First Order from the University Hospital of Salamanca, A New Clinical Routine Customer in Spain

New 90-day low - kr.57.00

First half earnings released

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera